These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 16487843)

  • 1. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
    Vyas AK; Guo H; Moss AJ; Olshansky B; McNitt SA; Hall WJ; Zareba W; Steinberg JS; Fischer A; Ruskin J; Andrews ML;
    J Am Coll Cardiol; 2006 Feb; 47(4):769-73. PubMed ID: 16487843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
    Daubert JP; Zareba W; Hall WJ; Schuger C; Corsello A; Leon AR; Andrews ML; McNitt S; Huang DT; Moss AJ;
    J Am Coll Cardiol; 2006 Jan; 47(1):98-107. PubMed ID: 16386671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
    Singh JP; Hall WJ; McNitt S; Wang H; Daubert JP; Zareba W; Ruskin JN; Moss AJ;
    J Am Coll Cardiol; 2005 Nov; 46(9):1712-20. PubMed ID: 16256874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
    Haigney MC; Zareba W; Gentlesk PJ; Goldstein RE; Illovsky M; McNitt S; Andrews ML; Moss AJ;
    J Am Coll Cardiol; 2004 Oct; 44(7):1481-7. PubMed ID: 15464332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study.
    Klein G; Lissel C; Fuchs AC; Gardiwal A; Oswald H; Desousa M; Pichlmaier AM; Lichtinghagen R; Geerlings H; Lippolt P; Niehaus M; Drexler H; Korte T
    Europace; 2006 Aug; 8(8):618-24. PubMed ID: 16864615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients.
    Pietrasik G; Goldenberg I; McNitt S; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2007 Feb; 18(2):181-4. PubMed ID: 17338766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effect?
    Beri A; Contractor T; Khasnis A; Thakur R
    Am J Cardiovasc Drugs; 2010; 10(3):155-64. PubMed ID: 20524717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.
    Moss AJ; Greenberg H; Case RB; Zareba W; Hall WJ; Brown MW; Daubert JP; McNitt S; Andrews ML; Elkin AD;
    Circulation; 2004 Dec; 110(25):3760-5. PubMed ID: 15583079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in life-threatening ventricular tachyarrhythmias in statin-treated patients with nonischemic cardiomyopathy enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy).
    Buber J; Goldenberg I; Moss AJ; Wang PJ; McNitt S; Hall WJ; Eldar M; Barsheshet A; Shechter M
    J Am Coll Cardiol; 2012 Aug; 60(8):749-55. PubMed ID: 22703927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
    Zarraga IG; Dougherty CM; MacMurdy KS; Raitt MH
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):739-47. PubMed ID: 22773022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of statin therapy on ventricular tachyarrhythmias: a meta-analysis.
    Wanahita N; Chen J; Bangalore S; Shah K; Rachko M; Coleman CI; Schweitzer P
    Am J Ther; 2012 Jan; 19(1):16-23. PubMed ID: 20720485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Short-term and long-term outcome of left heart function after cardioverter defibrillator implantation].
    Takeichi K; Kasanuki H; Ohnishi S; Endoh Y; Hosoda S
    J Cardiol; 1996 Nov; 28(5):277-86. PubMed ID: 8953401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverter-defibrillators.
    Buxton AE; Sweeney MO; Wathen MS; Josephson ME; Otterness MF; Hogan-Miller E; Stark AJ; Degroot PJ;
    J Am Coll Cardiol; 2005 Jul; 46(2):310-6. PubMed ID: 16022960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
    Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
    Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
    Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
    Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender differences in ventricular arrhythmia recurrence in patients with coronary artery disease and implantable cardioverter-defibrillators.
    Lampert R; McPherson CA; Clancy JF; Caulin-Glaser TL; Rosenfeld LE; Batsford WP
    J Am Coll Cardiol; 2004 Jun; 43(12):2293-9. PubMed ID: 15193696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II.
    Steinberg JS; Fischer A; Wang P; Schuger C; Daubert J; McNitt S; Andrews M; Brown M; Hall WJ; Zareba W; Moss AJ;
    J Cardiovasc Electrophysiol; 2005 Apr; 16(4):359-65. PubMed ID: 15828875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.